Welcome to our dedicated page for PaxMedica news (Ticker: PXMD), a resource for investors and traders seeking the latest updates and insights on PaxMedica stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PaxMedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PaxMedica's position in the market.
PaxMedica, a clinical stage biopharmaceutical company, announced its participation in the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference on December 1, 2022, in New York City. CEO Zachary Rome will conduct one-on-one meetings with institutional analysts and investors to discuss PaxMedica's focus on novel anti-purinergic drug therapies for conditions like Autism Spectrum Disorder and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. The conference connects emerging companies with investors in a personalized format.
PaxMedica has secured a flexible $20 million funding agreement with Lincoln Park Capital to accelerate its development of PAX-101, a drug targeting neurological disorders. This arrangement allows PaxMedica to sell shares over 30 months without financial covenants, providing funds for manufacturing validation and an upcoming NDA submission for treating Human African Trypanosomiasis. CEO Howard Weisman highlighted that this funding will support growth and could lead to the monetization of a Priority Review Voucher upon NDA acceptance.
PaxMedica, a clinical-stage biopharmaceutical company focused on anti-purinergic therapies, has strengthened its executive team by appointing Stephen D. Sheldon as CFO and Dr. Stefan Schwabe as CMO. As of Q3 2022, the company reported $5.6 million in cash and a lean cost structure post-IPO. In November, they initiated a Phase 3 trial for PAX-101 targeting Stage 1 TBR HAT, with results expected in H1 2023. CEO Howard Weisman emphasized the significance of these developments as the company progresses in its strategic goals.
PaxMedica, Inc. (Nasdaq: PXMD) has initiated a Phase 3 trial, HAT-301, to evaluate PAX-101 (intravenous suramin) for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis. Conducted in Uganda and Malawi, the trial aims to prove suramin's effectiveness compared to untreated patient data. Successful results may support a New Drug Application (NDA) for PAX-101, potentially qualifying for a priority review voucher from the FDA. Final study results are anticipated in the first half of 2023, aligning with PaxMedica's strategy to advance treatments for neurological conditions.
PaxMedica, a clinical-stage biopharmaceutical company, has appointed Dr. Stefan Schwabe as Chief Medical Officer. With over 30 years of experience in the pharmaceutical industry, Dr. Schwabe will lead product development, focusing on anti-purinergic therapies for neurological disorders like autism spectrum disorder. CEO Howard Weisman expressed optimism about Dr. Schwabe's contributions as the company advances its clinical programs, particularly for its lead compound, PAX-101, which shows promise in treating ASD. The appointment signals a strategic move to strengthen leadership amid ongoing clinical developments.
PaxMedica, Inc. (Nasdaq: PXMD) announces the appointment of Charles (Chuck) J. Casamento to its Board of Directors, effective October 1, 2022. With over 40 years of industry experience, Casamento will also chair the Audit Committee. CEO Howard Weisman highlighted his extensive background in building pharmaceutical companies as pivotal for PaxMedica's growth, especially in developing treatments for autism spectrum disorders. Casamento's previous leadership roles include founding Questcor Pharmaceuticals and serving on multiple public company boards.
PaxMedica, Inc. (Nasdaq:PXMD), a clinical-stage biopharmaceutical company, priced its initial public offering (IPO) at $5.25 per share, aiming to raise approximately $8.1 million before expenses. The offering includes 1,545,454 shares, with an option for underwriters to purchase an additional 231,818 shares. Shares are set to commence trading on the Nasdaq Capital Market on August 26, 2022, with the offering expected to close around August 30, 2022. PaxMedica focuses on anti-purinergic therapies for disorders like Autism Spectrum Disorder and chronic fatigue syndrome.